GlassScriptPhysician profile
Reid D Castellone
NPI 1154708543
$7,533.27
in general payments reported to CMS, 2019-2025
65 companies · $1,271 in 2025
The $1,271 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $1,128 · 2021: $1,647 · 2022: $1,113 · 2023: $282 · 2024: $654 · 2025: $1,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $577.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $563.46 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $531.60 | 2019-2025 | |
| Lilly USA, LLC | $462.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $317.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $316.87 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $261.10 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $257.61 | 2021-2023 | Qelbree |
| Novartis Pharmaceuticals Corporation | $254.73 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $212.10 | 2019-2022 | |
| Amgen INC. | $200.85 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.82 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $172.80 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $157.70 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reid Castellone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.